Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifinatamab Deruxtecan (I-DXd) vs Treatment of Physician's Choice in Relapsed Small Cell Lung Cancer
NCT06203210Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2024
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of ifinatamab deruxtecan in small cell lung cancer (SCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started May 2024; status: recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06203210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06203210.